Why Is BridgeBio Stock Gaining Monday? - BridgeBio Pharma ( NASDAQ:BBIO )
BridgeBio Pharma, Inc. ( NASDAQ: BBIO ) on Sunday presented data from the ATTRibute-CM study.
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo ...
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
PALO ALTO, Calif., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials oral presentation, one oral presentation, ...
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseline ...
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 ( ADH1 ) Investor Webinar on Wednesday, September 10th at 8:00 am ET
PALO ALTO, Calif., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at ...
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
PALO ALTO, Calif., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism ...
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality ( CVM ) through Month 42 of the ATTRibute-CM Open Label Extension
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ...
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality ( CVM ) through Month 42 of the ATTRibute-CM Open Label Extension - BridgeBio Pharma ( NASDAQ:BBIO )
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM
BridgeBio to Participate in September Investor Conferences
PALO ALTO, Calif., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following ...
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
PALO ALTO, Calif., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data ...
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition - Helix Acquisition Corp ( NASDAQ:HLXB )
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity ( "PIPE" ) , led by Cormorant
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
BBOT Debuts as Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition ...
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
BOSTON & SOUTH SAN FRANCISCO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Helix Acquisition Corp. II ( "Helix" ) ( Nasdaq: HLXB ) , a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and TheRas, Inc. ( d/b/a BridgeBio Oncology Therapeutics ) ( "BBOT" ) , a ...
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - BridgeBio Pharma ( NASDAQ:BBIO ) , Helix Acquisition Corp ( NASDAQ:HLXB )
Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing 2nd lowest redemption rate for a biotech de-SPAC transaction since 2022
BridgeBio Pharma ( BBIO ) Reports Q2 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -14.46% and +14.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Check Out What Whales Are Doing With BBIO - BridgeBio Pharma ( NASDAQ:BBIO )
Investors with a lot of money to spend have taken a bullish stance on BridgeBio Pharma BBIO. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Analysts Estimate Amphastar Pharmaceuticals ( AMPH ) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma ( BBIO ) Expected to Beat Earnings Estimates: Should You Buy?
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
- By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates1 ( 3.9 per 100,000 ) , which equates to approximately 25,000 carriers of ...
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination - BridgeBio Pharma ( NASDAQ:BBIO ) , Helix Acquisition Corp ( NASDAQ:HLXB )
SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 ( GLOBE NEWSWIRE ) -- Helix Acquisition Corp.
Is Pfizer Stock a Yield Trap?
When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.Patent-protected exclusivity is the reason pharmaceutical stocks are known for delivering reliably ...
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
PALO ALTO, Calif., June 30, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced it has sold a portion of royalties due to the Company from sales of BEYONTTRA in ...
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., June 26, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
PALO ALTO, Calif., June 26, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET ...
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
PALO ALTO, Calif., June 02, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the ...
The Smart Money Is Buying These 10 Stocks - Apollo Global Management ( NYSE:APO ) , AppLovin ( NASDAQ:APP )
Private equity titans like Apollo, Blackstone and KKR have to reveal what stocks they own every quarter. Copying their investments has beaten the markets 4-to-1 since 2001. Here are KKR's top ten public holdings.
Are Medical Stocks Lagging Alignment Healthcare ( ALHC ) This Year?
Here is how Alignment Healthcare (ALHC) and BridgeBio Pharma (BBIO) have performed compared to their sector so far this year.
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo ...
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete ( ≥90% ) TTR ...
Wall Street Analysts Believe BridgeBio Pharma ( BBIO ) Could Rally 63.87%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
- ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients ( 59.1% risk reduction ) , establishing the mechanistic hypothesis that stabilizing TTR may ...
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., May 12, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., May 07, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
BridgeBio Pharma ( BBIO ) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 12% and 86.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
BEYONTTRA® ( acoramidis ) , the First Near-complete TTR Stabilizer ( ≥90% ) , Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date ...
Bausch Health ( BHC ) Reports Next Week: Wall Street Expects Earnings Growth
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., April 22, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. BBIO ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market ...
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
PALO ALTO, Calif., April 22, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates ...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., April 11, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
PALO ALTO, Calif., March 31, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, today presented results showing statistically significant improvements in clinical outcomes as ...
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - BridgeBio Pharma ( NASDAQ:BBIO )
Japan approved BridgeBio's acoramidis ( Beyonttra ) for ATTR-CM, with AstraZeneca's Alexion handling commercialization. BridgeBio will receive a $30 million milestone payment and low double-digit royalties, with launch expected in H1 2025. Pelosi's latest AI pick skyrocketed 169% in just one ...
Beyonttra™ ( acoramidis ) , the First Near-complete TTR Stabilizer ( ≥90% ) , Approved in Japan to Treat ATTR-CM - BridgeBio Pharma ( NASDAQ:BBIO )
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated In as few as 3 months, the time to first event ( all-cause mortality ( ACM ) or cardiovascular-related hospitalization ( CVH ) ) durably separated relative to placebo.
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy ( ATTR-CM ) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
PALO ALTO, Calif., March 24, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM ...
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy ( ATTR-CM ) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - BridgeBio Pharma ( NASDAQ:BBIO )
PALO ALTO, Calif., March 24, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 ( c ) ( 4 )
PALO ALTO, Calif., March 21, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( "BridgeBio" or the "Company" ) , a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on March 19, 2025, the compensation committee of BridgeBio's board of ...
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt - BridgeBio Pharma ( NASDAQ:BBIO )
Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity Offering priced at 1.75% interest rate and 45% conversion premium PALO ALTO, Calif., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc.
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
PALO ALTO, Calif., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Pharma, Inc. ( Nasdaq: BBIO ) ( the "Company," "we" or "BridgeBio" ) announced today the pricing of $500 million aggregate principal amount of 1.75% convertible senior notes due 2031 ( the "notes" ) in a private offering ( the ...
